WEKO3
インデックスリンク
アイテム
Randomized, Phase II Study Comparing Interferon Combined with Hepatic Arterial Infusion of Fluorouracil plus Cisplatin and Fluorouracil Alone in Patients with Advanced Hepatocellular Carcinoma
https://doi.org/10.24517/00013605
https://doi.org/10.24517/0001360524363766-9cbd-4ba4-8e09-7d7fc642368a
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
ME-PR-YAMASHITA-T-281.pdf (413.5 kB)
|
.png)
|
| Item type | 学術雑誌論文 / Journal Article(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2017-10-03 | |||||
| タイトル | ||||||
| タイトル | Randomized, Phase II Study Comparing Interferon Combined with Hepatic Arterial Infusion of Fluorouracil plus Cisplatin and Fluorouracil Alone in Patients with Advanced Hepatocellular Carcinoma | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
| 資源タイプ | journal article | |||||
| ID登録 | ||||||
| ID登録 | 10.24517/00013605 | |||||
| ID登録タイプ | JaLC | |||||
| 著者 |
Yamashita, Tatsuya
× Yamashita, Tatsuya× Arai, Kuniaki× Sunagozaka, Hajime× Ueda, Teruyuki× Terashima, Takeshi× Yamashita, Taro× Mizukoshi, Eishiro× Sakai, Akito× Nakamoto, Yasunari× Honda, Masao× Kaneko, Shuichi |
|||||
| 著者別表示 |
山下, 竜也
× 山下, 竜也× 荒井, 邦明× 砂子坂, 肇× 上田, 晃之× 寺島, 健志× 山下, 太郎× 水腰, 英四郎× 中本, 安成× 本多, 政夫× 金子, 周一 |
|||||
| 提供者所属 | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | 金沢大学先進予防医学研究センター / 金沢大学医薬保健研究域医学系 | |||||
| 書誌情報 |
Oncology 巻 81, 号 5-6, p. 281-290, 発行日 2011-11-30 |
|||||
| ISSN | ||||||
| 収録物識別子タイプ | ISSN | |||||
| 収録物識別子 | 0030-2414 | |||||
| NCID | ||||||
| 収録物識別子タイプ | NCID | |||||
| 収録物識別子 | AA00764146 | |||||
| DOI | ||||||
| 関連タイプ | isVersionOf | |||||
| 識別子タイプ | DOI | |||||
| 関連識別子 | 10.1159/000334439 | |||||
| 出版者 | ||||||
| 出版者 | Karger | |||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | Objective: This randomized phase II trial compared the response rates to treatment with interferon (IFN) combined with hepatic arterial infusion of fluorouracil (FU) plus cisplatin (CDDP) or FU alone in patients with advanced hepatocellular carcinoma (HCC). Methods: A total of 114 patients with measurable advanced HCC were enrolled and randomized into 2 groups. FU (300 mg/m2, days 1–5, days 8–12) with or without CDDP (20 mg/m2, days 1 and 8) was administered via the hepatic artery. IFNα-2b was administered 3 times per week for 4 weeks. Results: The response rates were 45.6% for the IFN/FU + CDDP group and 24.6% for the IFN/FU group. The response rate was significantly higher in the IFN/FU + CDDP group (p = 0.030). The median overall survival period was 17.6 months in the IFN/FU + CDDP group versus 10.5 months in the IFN/FU group (p = 0.522). The median progression-free survival period was 6.5 months in the IFN/FU + CDDP group versus 3.3 months in the IFN/FU group (p = 0.0048). Hematological toxicity was common, but no toxicity-related deaths were observed. Conclusion: These results show the clinical efficacy of adding CDDP to the hepatic arterial infusion of FU in combined chemotherapy regimens with IFN. | |||||
| 著者版フラグ | ||||||
| 出版タイプ | AM | |||||
| 出版タイプResource | http://purl.org/coar/version/c_ab4af688f83e57aa | |||||
